Thus, in the future it may be desirable to investigate whether recombinant GH administration may have a role also in adolescents with obesity and progressing MAFLD, in order to prevent the hepatic damage induced by steatosis, which appears to increasingly lead to the appearance of cirrhosis already in young adulthood. This evidence concerns the gene GH1 and steatosis.